[Efficacy and tolerability of nabumetone in the treatment of painful symptomatology of rheumatoid arthritis and osteoarthrosis].
We evaluated the effectiveness and the tolerability of a new non steroidal antiinflammatory drug (NSAID), nabumetone (1 g/daily for at least 8 days), in 20 patients (10 males and 10 females), 4 with rheumatoid arthritis and 16 with osteoarthritis. During the treatment we observed a progressive reduction of pain and swelling with improvement of articular movements. Our results showed an appreciable effectiveness of nabumetone treatment in 75% of patients. Excluding two patients with transient mild side effects (gastric and cutaneous symptoms), the tolerability has been satisfactory.
Riccieri
V
V
Istituto di Reumatologia, Università degli Studi di Roma La Sapienza.
Spadaro
A
A
Iagnocco
A
A
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002074:Butanones / Q000627:therapeutic use*; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077430:Nabumetone; D010003:Osteoarthritis / Q000188:drug therapy*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D000077430:Nabumetone
Efficacia e tollerabilità del nabumetone nella terapia della sintomatologia dolorosa dell'artrite reumatoide e dell'osteoartrosi.